MEMORANDUM #139

TO: UNCHCS Attending Physicians, Housestaff, Department Heads and Supervisors

FROM: Nichole Korpi-Steiner, Ph.D., Director, Special Chemistry Laboratory
John Schmitz, Ph.D., Associate Director, Clinical Microbiology/Immunology Laboratories
Eric Weimer, Ph.D., Associate Director, Clinical Microbiology/Immunology Laboratories
Maya Styner, M.D., Endocrinology and Metabolism
Peter Gilligan, Ph.D., Director, Clinical Microbiology/Immunology Laboratories
Herbert C. Whinna, M.D., Ph.D., Medical Director, McLendon Clinical Laboratories

SUBJECT: Changes to 25-Hydroxy Vitamin D testing

DATE: January 5, 2017

Effective January 8th 2018, 25-Hydroxy Vitamin D testing will change from a laboratory developed test using mass spectrometry to a FDA-approved test that uses immunoassay methodology which is certified by the CDC Vitamin D Standardization Certification Program.

Impact on patient 25-Hydroxy Vitamin D testing:

- Test order code "Vitamin D (25-Hydroxy)" will not change.
- Reference intervals will not change.
- Total 25-Hydroxy Vitamin D values will continue to be reported.
- Vitamin D2 and D3 value reporting will be discontinued.
- Total 25-Hydroxy Vitamin D testing ordered on or after January 8th, 2017 will report lower values than previously reported due to analytical differences between the new and current methods of testing.
  [New method 25-HydroxyVitD] = 0.93[Current method 25-HydroxyVitD] – 2.56
- **Please note that a decrease in 25-Hydroxy Vitamin D level may or may not indicate an actual change in the patient's 25-Hydroxy Vitamin D level.**
- The following chart demonstrates the degree of expected difference between the new and current methods at various 25-Hydroxy Vitamin D levels:

25-HydroxyVit D Range (ng/mL)	Mean Bias (ng/mL; New Method compared with Current Method)	%CV
5 to 20	-0.9	0.18
20 to 30	-2.6	0.16
30 to 40	-8.6	0.18
40 to 50	-8	0.15

If you have any questions related to these changes, please contact the Clinical Immunology Laboratory at 984-974-1815.